Monopar Therapeutics Inc. (MNPR) vs Oculis Holding AG (OCS)
A side-by-side comparison of Monopar Therapeutics Inc. and Oculis Holding AG across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MNPR
Monopar Therapeutics Inc.
$77.90HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT
OCS
Oculis Holding AG
$8.64HealthcareDelayed quote: Oct 6, 2026, 12:50 PM EDT
Total return — MNPR vs OCS
growth of $100 · dividends reinvested · last 5yMNPR +183.7% (+23.2%/yr)OCS -11.8% (-2.5%/yr)MNPR compounded faster over this window
MNPR OCS
MNPR vs OCS: by the numbers
- •MNPR is the larger company ($522M vs $494M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -32724.20% net margin).
Metrics side by side
Valuation
| Metric | MNPR | OCS |
|---|---|---|
| P/S ratio | N/A | 1619.03 |
| P/B ratio | 3.99 | 1.82 |
Profitability
| Metric | MNPR | OCS |
|---|---|---|
| Gross margin | 0.00% | 0.00% |
| Operating margin | 0.00% | 0.00% |
| Net margin | 0.00% | -32724.20% |
| ROE | -13.64% | -36.79% |
| ROIC | -16.89% | -39.63% |
Growth (annualized)
| Metric | MNPR | OCS |
|---|---|---|
| Total return CAGR (5Y) | 27.38% | -2.41% |
Frequently asked
- How have MNPR and OCS total returns compared?
- Over the past 5 years, MNPR delivered 27.38% and OCS delivered -2.41% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.